- New study shows men were more than twice as likely to develop serious heart condition, infective endocarditis, as women
- IE is a serious heart infection that kills around a third of those who develop it within the first year
- The new study allows prevention measures to be targeted at those individuals most at risk of developing IE
A team of international researchers, led by the University of Sheffield, have measured the risk of developing or dying from the life-threatening heart condition infective endocarditis (IE), for people with predisposed heart conditions.
The new study, led by Professor Martin Thornhill from the University of Sheffield’s School of Clinical Dentistry, shows that men were more than twice as likely to develop IE as women and that the risk peaked in young children and the elderly.
“Those with artificial or repaired heart valves and certain congenital heart conditions were at much higher risk of developing or dying from IE than the general population,” said Professor Thornhill.
“And the risk of developing IE again was even higher in those who previously had IE.
“Surprisingly, the risk of IE was substantially reduced in those with repaired congenital heart defects although those in whom the repair involved shunts or conduits had a much higher and progressively worsening risk of developing or dying from IE.”
In recent years there has been an increasing number of people in whom implantable pacemakers and defibrillators have been inserted to treat heart problems and the study showed for the first time that these individuals also have an increased risk of IE.
IE is a serious heart infection that kills around a third of those who develop it within the first year and causes long-term and serious disability in those who survive.
The findings, published in the European Heart Journal, are particularly important because they allow prevention measures to be targeted at those individuals most at risk of developing IE and they allow clinicians and patients to better evaluate the risk of this complication before procedures such as artificial heart valves, implanted pacemakers are performed.
These findings may also help international guideline committees to improve their guidance on the prevention of IE and the risks associated with different cardiac procedures.
This research was funded by Heart Research-UK and The US National Institutes for Health.
The University of Sheffield
With almost 27,000 of the brightest students from over 140 countries, learning alongside over 1,200 of the best academics from across the globe, the University of Sheffield is one of the world’s leading universities.
A member of the UK’s prestigious Russell Group of leading research-led institutions, Sheffield offers world-class teaching and research excellence across a wide range of disciplines.
Unified by the power of discovery and understanding, staff and students at the university are committed to finding new ways to transform the world we live in.
Sheffield is the only university to feature in The Sunday Times 100 Best Not-For-Profit Organisations to Work For 2017 and was voted number one university in the UK for Student Satisfaction by Times Higher Education in 2014. In the last decade it has won four Queen’s Anniversary Prizes in recognition of the outstanding contribution to the United Kingdom’s intellectual, economic, cultural and social life.
Sheffield has six Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields.
Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, Glaxo SmithKline, Siemens and Airbus, as well as many UK and overseas government agencies and charitable foundations.